News

404

The CREB-binding protein (CBP)/β-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)

PRISM BioLab raised 100 million yen in Series C funding from Eisai

PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics™”, today announced that it has raised ¥100 million in Series C funding through a third-party allotment to Eisai Co. Ltd. on October 14. PRISM has completed the series C financing of 1.4 billion yen in total and aims to achieve...

The paper of peptidomimetics is published in ACS Omega

This paper presents the new method to analyze how peptidomimetics scaffold mimic the actual peptide, and PRISM’s scaffold advantage is confirmed.
Visualized and Quantitative Conformational Analysis of Peptidomimetics
ACS omega, 6(40), 26601-26612 (2021)

PRISM BioLab raised 1.3 billion yen in Series C funding

PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics™”, today announced that it has raised a total of ¥1.3 billion in Series C funding on August 27. Read Full Press Release

E7386, a selective inhibitor of the interaction between β-catenin and CBP, exerts antitumor activity in tumor models with activated canonical wnt signaling

Cancer Research, 81(4), 1052-1062 (2021)
Yamada, Kazuhiko; Hori, Yusaku; Inoue, Satoshi; Yamamoto, Yuji; Iso, Kentaro; Kamiyama, Hiroshi; Yamaguchi, Atsumi; Kimura, Takayuki; Uesugi, Mai; Ito, Junichi; Matsuki, Masahiro; Nakamoto, Kazutaka; Harada, Hitoshi; Yoneda, Naoki; Takemura, Atsushi; Kushida, Ikuo; Wakayama, Naomi; Kubara, Kenji; Kato, Yu; Semba, Taro; Yokoi, Akira; Matsukura, Masayuki; Odagami, Takenao; Iwata, Masao; Tsuruoka, Akihiko; Uenaka, Toshimitsu; Matsui, Junji; Matsushima, Tomohiro; Nomoto, Kenichi; Kouji, Hiroyuki; Owa, Takashi; Funahashi, Yasuhiro; Ozawa, Yoichi

Scroll to top
en_USEnglish